An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

Hu Jingbo; Yang Chunlin; Wang Hongbo; Li Jing; Tan Xueying; Wang Jinhui; Zhang Bin; Zhao Yufen

首页> 外文期刊>Expert opinion on pharmacotherapy >An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

【24h】

An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

机译：Alogliptin Benzoate治疗2型糖尿病的最新评价

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: A growth in the market for anti-diabetic drugs, along with an ever-increasing population suffering from type 2 diabetes mellitus (T2DM), requires a critical re-evaluation of anti-diabetic drugs used for a long time, in order to provide up-to-date practical prescribing information for clinicians. Alogliptin benzoate was firstly approved in 2010 in Japan for T2DM, both as a monotherapy or in combination with other anti-diabetic drugs. Areas covered: This article provides a comprehensive review of the latest data on alogliptin benzoate, including hypoglycemic activity and safety. Expert opinion: The cumulative evidence for alogliptin benzoate is robust with regards to glycemic efficacy and safety. Low hypoglycemia risks and weight changes support its consideration as a first-line medication for T2DM, either as a monotherapy or in combination therapy with other anti-diabetic drugs such as metformin. Ongoing trials will look to better analyze and address its safety and efficacy in pediatric patients and expand our clinical knowledge of this medication.

机译：介绍：抗糖尿病药物市场的增长以及患有2型糖尿病（T2DM）的患者的不断增长的人口，需要致力于使用长期使用的抗糖尿病药物的重新评估，以便为临床医生提供最新的实际处方信息。 Alogliptin Benzoate于2010年在日本首次批准T2DM，无论是单药治疗还是与其他抗糖尿病药物组合。所涵盖的区域：本文对Alogliptin Benzoate的最新数据进行了全面审查，包括降血糖活动和安全。专家意见：Alogliptin Benzoate的累积证据对血糖疗效和安全性方面是强大的。低低血糖风险和重量变化支持其考虑作为T2DM的一线药物，作为单药治疗或与其他抗糖尿病药物如二甲双胍的联合治疗。正在进行的试验将希望更好地分析和解决儿科患者的安全性和疗效，并扩大我们对这种药物的临床知识。

著录项

来源
《Expert opinion on pharmacotherapy》 |2019年第18期|共9页
作者
Hu Jingbo; Yang Chunlin; Wang Hongbo; Li Jing; Tan Xueying; Wang Jinhui; Zhang Bin; Zhao Yufen;
展开▼
作者单位

Ningbo Univ Inst Drug Discovery Technol Ningbo 315000 Zhejiang Peoples R China;

Ningbo Univ Affiliated Yangming Hosp Dept Pharm Yuyao Peoples R China;

Ningbo Univ Affiliated Yangming Hosp Dept Pharm Yuyao Peoples R China;

Ningbo Univ Affiliated Yangming Hosp Dept Pharm Yuyao Peoples R China;

Zhejiang Pharmaceut Coll Coll Pharm Ningbo Zhejiang Peoples R China;

Ningbo Univ Inst Drug Discovery Technol Ningbo 315000 Zhejiang Peoples R China;

Ningbo Univ Coll Food &

Pharmaceut Sci Li Dak Sum Yip Yio Chin Kenneth Li Marine Biophar Ningbo;

Ningbo Univ Inst Drug Discovery Technol Ningbo 315000 Zhejiang Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
DPP-4 inhibitor; alogliptin benzoate; type 2 diabetes mellitus; up-to-date evaluation;

机译：DPP-4抑制剂;Alogliptin Benzoate;2型糖尿病;最新评估;

相似文献

外文文献
中文文献
专利

1. An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes [J] . Hu Jingbo, Yang Chunlin, Wang Hongbo, Expert opinion on pharmacotherapy . 2019,第13a18期

机译：Alogliptin Benzoate治疗2型糖尿病的最新评价
2. Alogliptin benzoate for the treatment of type 2 diabetes. [J] . Marc Rendell, Andjela Drincic, Radha Andukuri Expert opinion on pharmacotherapy . 2012,第4期

机译：阿格列汀苯甲酸酯用于治疗2型糖尿病。
3. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting [J] . W. David Strain, Phil McEwan, Heena Howitt, Diabetes therapy . 2019,第4期

机译：回顾性数据库分析评估在初级保健机构中将其他DPP-4抑制剂治疗改为阿格列汀治疗2型糖尿病（T2DM）患者的治疗改变的临床结果
4. CloudConnect: Evaluating the use of precision medicine in treatment of Type 1 Diabetes [C] . Jonathan Bae, John Corbett, James Kim, Systems and Information Engineering Design Symposium . 2017

机译：CloudConnect：评估精准药物在1型糖尿病治疗中的使用
5. Inflammation, Type 2 Diabetes, and Cancer: Identifying Biomarkers Associated with Colorectal Cancer and Type 2 Diabetes, and the Use of microRna Molecules as a Therapeutic Use for Cancer Treatment [D] . Guillen, Jenni. 2020

机译：炎症，2型糖尿病和癌症：鉴定与结肠直肠癌和2型糖尿病相关的生物标志物，以及使用MicroRNA分子作为癌症治疗的治疗用途
6. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting [O] . W. David Strain, Phil McEwan, Heena Howitt, 2019

机译：回顾性数据库分析评估临床2D糖尿病（T2DM）患者从其他DPP-4抑制剂疗法改为阿格列汀治疗的临床结局
7. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting [O] . W. David Strain, Phil McEwan, Heena Howitt, 2019

机译：回顾性数据库分析评估从其他DPP-4抑制剂治疗到Alogliptin在初级保健环境中改变患有2型糖尿病（T2DM）的临床结果

An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

摘要

著录项

相似文献

相关主题

期刊订阅